FDA approves Cassiopea's WINLEVI (CB-03-01, 1% formulation) for Acne Technology 8/27/2020
The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.
View this post in the Community →
Similar Community Posts Join
6 / 97 resultscommunity Cassiopea Announces Very Positive Interim Analysis Phase 2 Results for Breezula® (Clascoterone) in Treating Androgenetic Alopecia
Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.
community CASSIOPEA ANNOUNCES VERY POSITIVE PHASE II TWELVE MONTHS RESULTS FOR BREEZULA® (CLASCOTERONE) IN TREATING ANDROGENETIC ALOPECIA
Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.
community Will you try clascosterone when it gets released?
People are interested in trying clascosterone (Breezula) for hair loss, especially those who are too young for finasteride. Some users express concerns about the cost and prescription requirements, while others discuss alternatives like RU58841.
community Clascoterone - Why are there so few posts if it’s already on the market?
Clascoterone is being discussed for hair loss, but its current acne formulation may not be suitable for scalp use due to potential skin irritation and lower dosage compared to Breezula. Users mention other treatments like finasteride, minoxidil, and pyrilutamide, with some expressing skepticism about clascoterone's effectiveness for hair loss.
community Winlevi coming out in 2019
The conversation discusses the potential release of Winlevi in 2019 by Cassiopeia for hair loss treatment. It suggests a regimen combining minoxidil, Winlevi, Nizoral, and possibly dermarolling, with a comment mentioning Breezula as an alternative to finasteride without side effects.
community Clascoterone - what we have right now
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
Related Research
6 / 13 resultsresearch Clascoterone: First Approval
Clascoterone cream was approved in the USA for treating acne in people aged 12 and older.
research Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris
Topical therapies show promise for hair loss and acne treatment with minimal side effects.
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Industry Update: The Latest Developments in the Field of Therapeutic Delivery, July 2018
New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
research Androgens and Acne: Perspectives on Clascoterone, the First Topical Androgen Receptor Antagonist
Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
research Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
Clascoterone 1% cream is a promising new treatment for acne.